Donor-specific antibodies development in renal living-donor receptors: Effect of a single cohort

Int J Immunopathol Pharmacol. 2021 Jan-Dec:35:20587384211000545. doi: 10.1177/20587384211000545.

Abstract

Minimization in immunosuppression could contribute to the appearance the donor-specific HLA antibodies (DSA) and graft failure. The objective was to compare the incidence of DSA in renal transplantation (RT) in recipients with immunosuppression with and without steroids. A prospective cohort from March 1st, 2013 to March 1st, 2014 and follow-up (1 year), ended in March 2015, was performed in living donor renal transplant (LDRT) recipients with immunosuppression and early steroid withdrawal (ESW) and compared with a control cohort (CC) of patients with steroid-sustained immunosuppression. All patients were negative cross-matched and for DSA pre-transplant. The regression model was used to associate the development of DSA antibodies and acute rejection (AR) in subjects with immunosuppressive regimens with and without steroids. Seventy-seven patients were included (30 ESW and 47 CC). The positivity of DSA class I (13% vs 2%; P < 0.05) and class II (17% vs 4%, P = 0.06) antibodies were higher in ESW versus CC. The ESW tended to predict DSA class II (RR 5.7; CI (0.93-34.5, P = 0.06). T-cell mediated rejection presented in 80% of patients with DSA class I (P = 0.07), and 86% with DSA II (P = 0.03), and was associated with DSA class II, (RR 7.23; CI (1.2-44), P = 0.03). ESW could favor the positivity of DSA. A most strictly monitoring the DSA is necessary for the early stages of the transplant to clarify the relationship between T-cell mediated rejection and DSA.

Keywords: acute rejection; donor-specific antibodies; immunosuppression; renal transplantation.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies / blood*
  • Antilymphocyte Serum / therapeutic use
  • Basiliximab / therapeutic use
  • Drug Administration Schedule
  • Female
  • Graft Rejection / blood*
  • Humans
  • Immunosuppression Therapy
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation*
  • Living Donors*
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Mycophenolic Acid / therapeutic use
  • Prednisone / administration & dosage*
  • Prospective Studies
  • Tacrolimus / therapeutic use
  • Withholding Treatment
  • Young Adult

Substances

  • Antibodies
  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Basiliximab
  • thymoglobulin
  • Mycophenolic Acid
  • Prednisone
  • Tacrolimus
  • Methylprednisolone